- Drugs
- Analgesics
- Anti-Convulsants
- Anti-Anxiety Drugs
- Anti-Psychotics
- Anti-Depressants
- Anti-Coagulants
- Others
- Surgery
Traumatic Brain Injury Treatment Market size was valued at USD 3.03 billion in 2022. It is expected to reach a value of USD 5.26 billion by 2029, growing at a CAGR of 8.2% from 2023 to 2029. Traumatic brain injury (TBI) or intracranial injury is an injury to brain due to external force to brain. TBI can be classified as mild, moderate, and severe brain injury. TBI may be occur due to falls, vehicle collision, and violence. Symptoms of traumatic brain injury include cognitive, physical, social, and behavioural symptoms and outcome can range from complete recovery to permanent disability and may causes death. TBI can be diagnosed by using computed tomography (CT) and magnetic resonance imaging (MRIs). In May 2016, Stemedica Cell Technologies, Inc. received FDA investigational new drug (IND) approval for mesenchymal stem cells to treat traumatic brain injury. Industry trends in the market are evolving, which will aid players in developing successful long-term strategies. Both established and emerging markets have implemented business growth techniques. COVID-19 is an unprecedented worldwide public health crisis that has impacted practically every business, and its long-term repercussions are expected to have an influence on industry growth during the projection period. Our continuous study is enhancing our research approach to guarantee that fundamental COVID-19 concerns and potential solutions are included. The research examines COVID-19 in light of changes in consumer behaviour and demand, purchasing patterns, supply chain re-routing, market dynamics, and government involvement. This market research report considers the influence of COVID-19 on the market and includes insights, analysis, projections, and predictions.
Study Period
Base Year
CAGR
Largest Market
Fastest Growing Market
Increase in the prevalence of brain traumatic injuries due to rise in number of road accidents and falls is expected to drives the global traumatic brain injuries market over the forecast period. Moreover, rise in number of geriatric population, increase in the R & D for innovation of newer products, promising pipeline products for TBIs, and entry of targeted therapies into the market are expected to boost the global traumatic brain injuries market. However, delayed disease diagnosis, lack of social awareness, and lack of government support for R&D activities are anticipated to restrain the growth of traumatic brain injuries market.
The traumatic brain injury treatment market size was valued at USD 3.03 billion in 2022
The traumatic brain injury treatment market key players are TEVA Pharmaceutical Industries Ltd. (Israel) Tenax Therapeutics (U.S.) Amarantus BioScience Holdings (U.S.) Neuren Pharmaceuticals Ltd (Australia) Grace Laboratories LLC. (Georgia) Banyan Biomarkers Inc. (U.S) Vasopharm GmbH Cognosci, Inc. (U.S.) Medicortex Finland Oy (Finland)
The traumatic brain injury treatment market drivers are ongoing product development and approval